#6 Teray

#### BOX SEQUENCE

PATENT 0147-0229P

TECH CENTER 1600/29

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

NOV 0 5 2001

Helmut ECKERT et al.

Conf.:

2392

Appl. No.:

09/889,300

Group:

UNASSIGNED

Filed:

July 13, 2001

Examiner: UNASSIGNED

For:

USE OF ANTIBODIES FOR THE VACCINATION

AGAINST CANCER

### LETTER SUBMITTING COMPUTER READABLE FORM OF SEQUENCE LISTING

Assistant Commissioner for Patents Washington, DC 20231

November 5, 2001 (Monday)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 4, 2001, enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a disk copy of the Sequence Listing as originally filed on July 13, 2001. The disk copy of the Sequence Listing, file "2001-11-05 0147-0229P SL.txt", is identical to the paper copy filed July 13, 2001, except that it lacks formatting.

Docket No. 0147-0229P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

Attachments:

LRS/CAV 0147-0229P

Disk Copy of Sequence Listing

Copy of Notice to Comply

(Rev. 03/27/01)

Commissioner for Patents, Box PCT ed States Patent and Trademark Office Washington, D.C. 20231

AHI DI				
U.S. APPLICATION NO.	15 PE	FIRST NAMED APPLICA	ANT ·	ATTY, DOCKET NO.
09/8893	000	ECKERT	Н	0147-0229P
	NOV 0 5 2001 \$	2 1	INTERNA	TIONAL APPLICATION NO.
LEONARD R SVEN	T KOLAST BIRCH AREST		PC	T/EP00/00174
PO BOX 747			I.A. FILING D	ATE PRIORITY DATE
FAKLLS CHURCH,	VA 22040 0747		12 JAN 0	0 13 JAN 99

# NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

	×	The application fails to comply with the requirements of 37 CFR 1.821-1.825.
		This application does not contain, a "Sequence Listing" as a separate part of the
	ш	disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
		A copy of the "Sequence Listing" in computer readable format has not been submitted as
		required by 37 CFR 1.821(e).
		A copy of the "Sequence Listing" in computer readable form has been submitted. The
	_	content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
	$\Box$	The computer readable form that has been filed with this application has been found to be
	LJ	damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
		The paper copy or compact disc of the "Sequence Listing" is not the same as the
		computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
		Other:
A DOL I	<b>.</b>	NT MUST PROVIDE:
APPLI		A statistical are substitute computer readable form (CDF) of the "Sequence Listing"
	×	An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
		amendment directing its entry into the specification.  A statement that the contents of the paper or compact disc and the computer readable form
	X	are the same and, where applicable, include no new matter, as required by 37 CFR
		1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
		1.021(0); 1.021(1); 1.021(0); 1.021(1)

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

(703) 308-4216, for Rules interpretation,

(703) 308-4212, for CRF submission help,

U.S. APPLICATION NO.		FIRST NAMED APPL	ICANT		ATTY, DOCKET NO.
09/889300		ECKERT	Н		0147-0229P
		. /		INTERNATIONAL AF	PLICATION NO.
LEONARD R SVENSON BIRCH R STEWART KOI	LASH &BIRCH	DOCKETE!	) ≡S	PCT/EP00	0/00174
PO BOX 747		Perfect	·-·`   [	I.A. FILING DATE	PRIORITY DATE
FAKLLS CHURCH, VA 23	2040 0747	sequence Li	stryg	12 JAN 00	13 JAN 99
ł		U		DATE MAILED:	4 SEP 2001

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/IIS)

STATES DESIGNATED/ELECTED OFFICE (DO/EO/CS)	
1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark	긂
Office as a Designated Office (37 CFR 1.494) an Elected Office (37 CFR 1.495):	;;;
U.S. Basic National Fee. Indication of Small Entity Status.	古
Copy of the international application. Translation of the international application into English.	屰
Oath or Declaration of inventors(s). Translation of Article 19 amendments into English.	$\leq$
Copy of Article 19 amendments. Other:	꿇
Priority Document.	あ
The International Preliminary Examination Report in English and its Annexes, if any.	8
Translation of Annexes to the International Preliminary Examination Report into English.	TECH CENTER 1600/2900
2. [x] Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items	and/or
the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be prior to 20 or 30 months from the priority date to avoid abandonment.	æ filed
U.S. Basic National Fee. Copy of the international application.	
3. The following items <b>MUST</b> be furnished within the period set forth below in order to complete the requirements faceeptance under 35 U.S.C. 371:	or
a. Translation of the application into English. A processing fee will be required if submitted	
later than the appropriate 20 or 30 months from the priority date.	
The current translation is defective for the reasons indicated on the attached Notice of Defective	
Translation.  The processing fee for providing the translation of the application and/or the Annexes later than the	
appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).	
appropriate 20 of 30 months from the priority date (37 CFR 1.422(1)).  [ $\mathbf{x}$ ] c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying	g
the application (preferably by the International application number and international filing date). A	
surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.	
The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons	
indicated on the attached PCT/DO/EO/917.	
d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the	
priority date (37 CFR 1.492(e)).	d
4. Additional claim fees of \$ as a large entity small entity, including any required multiple depo	
claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fee due (37 CFR 1.492(g)). See attached PTO-875.	s are
5. Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.	
ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (	

THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date. 7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

## 532 Rec'd 7770 05 NOV 2001



#### BOX SEQUENCE

PATENT 0147-0229P

#### IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

Helmut ECKERT et al.

Conf.:

2392

RECEIVEL

Appl. No.:

09/889,300

Group:

UNASSIGNED

NOV 1 3 2001

Filed:

July 13, 2001

Examiner: UNASSIGNED

TECH CENTER 1600/290.

For:

USE OF ANTIBODIES FOR THE VACCINATION

AGAINST CANCER

RECEIVED

NOV 1 6 2001

SMALL ENTITY TRANSMITTAL FORM

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, DC 20231

November 5, 2001 (Monday)

Sir:

Transmitted herewith is a letter in the above-identified application.

$\boxtimes$	Applicant	claims	small	entity	status	under	37	C.F.R.	§	1.2	.7
-------------	-----------	--------	-------	--------	--------	-------	----	--------	---	-----	----

The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	11	11 - 11		=	0	\$ 9	\$0.00
INDEPENDENT 1 - 1		=	0	\$ 40	\$0.00		
FIRST PRESENTATION OF A MULTIPLE CLAIM						\$135	\$0.00
						TOTAL	\$0.00

Docket No. 0147-0229P

		. ) month(s) extension of time pursuant 1.136(a). \$0.00 for the extension of
$\boxtimes$	No fee is required.	
	A check in the amount o	f \$0.00 is enclosed.
	Please charge Deposit A \$0.00. This form is sub	Account No. $02-2448$ in the amount of mitted in triplicate.
	If necessary, the Commis	ssioner is hereby authorized in this,
conci	urrent, and future repli	es, to charge payment or credit any
overp	payment to Deposit Accour	nt No. 02-2448 for any additional fees
requi	ired under 37 C.F.R. §§1	.16 or 1.17; particularly, extension
of t	ime fees.	
		Respectfully submitted,
		BIRCH, STEWART, KOLASCH & BIRCH, LLP
I D.C. //		By 136, 623 Leonard R. Svensson, #30,330 P.O. Box 747
LRS/0	-0229P	Falls Church, VA 22040-0747 (703) 205-8000

(Rev. 01/22/01)

Attachment